Myelopathy in Sjögren's Syndrome: Role of Nonsteroidal Immunosuppressants

Drugs

Volumn 64, Issue 2, 2004, Pages 123-132

  Rogers, Susan J ^a,b   Williams, Christopher S ^c   Román, Gustavo C ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESNA; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AUTOIMMUNE DISEASE; BLADDER CANCER; BONE MARROW SUPPRESSION; BROWN SEQUARD SYNDROME; CANCER; CARCINOGENICITY; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HEMORRHAGIC CYSTITIS; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LIVER TOXICITY; LONG TERM EXPOSURE; LOW DRUG DOSE; LUNG TOXICITY; LYMPHOMA; MOTOR NEURON DISEASE; MYELITIS; NEPHROTOXICITY; NEUROGENIC BLADDER; NONHODGKIN LYMPHOMA; OPTIC NERVE DISEASE; PATHOGENESIS; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; REVIEW; SIDE EFFECT; SJOEGREN SYNDROME; SPINAL CORD; SPINAL CORD DISEASE; STOMATITIS; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; TREMOR; VASCULITIS; XEROSTOMIA;

CLINICAL TRIALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYELITIS, TRANSVERSE; SJOGREN'S SYNDROME; SPINAL CORD; SPINAL CORD DISEASES;

EID: 0442307474     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464020-00001     Document Type: Review

References (44)

1. Manoussakis MN, Moutsopoulos HM. Salivary gland diseases. Otolaryngol Clin North Am 1999 Oct; 32 (5): 844-61
2. Jonsson R, Haga HJ, Gordon TP, et al. Current concepts on diagnosis, autoantibodies and therapy in Sjögren's syndrome. Scand J Rheumatol 2000; 29: 341-8
3. Konttinen YT, Käsnä-Ronkainen L. Sjögren's syndrome: viewpoint on pathogenesis. Scand J Rheumatol 2002; 31 Suppl. 116: 15-22
4. Price EJ, Venables PJW. The etiopathogenesis of Sjögren's syndrome. Semin Arthritis Rheum 1995 Oct; 25 (2): 117-33
5. Fox RI, Stern M. Sjögren's syndrome: mechanisms of pathogenesis involve interaction of immune and neurosecretory systems. Scand J Rheumatol 2002; 31 Suppl. 116: 3-13
6. Lehrer S, Bogursky E, Yemini M, et al. Gynecologic manifestations of Sjögren's syndrome. Am J Obstet Gynecol 1994 Mar; 170 (3): 835-7
7. Harley JB, Reichlin M, Arnett FC, et al. Gene interaction at HLA-DQ enhances autoantibody production in primary Sjögren's syndrome. Science 1986 May; 232: 1145-7
8. Govoni M, Padovan M, Rizzo N, et al. CNS involvement in primary Sjögren's syndrome. CNS Drugs 2001; 15 (8): 597-607
9. Vincent TL, Richardson MP, Mackworth-Young CG, et al. Sjögren's syndrome-associated myelopathy: response to immunosuppressive treatment. Am J Med 2003 Feb 1; 114: 145-8
10. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. Ann Rheum Dis 1996; 55: 116-21
11. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis 2002; 61: 554-8
12. Fox RI, Saito I. Criteria for diagnosis of Sjögren's syndrome. Rheum Dis Clin North Am 1994 May; 20 (2): 391-407
13. Alexander EL. Neurologic disease in Sjögren's syndrome: mononuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle. Rheum Dis Clin North Am 1993 Nov; 19 (4): 869-908
14. Williams CS, Butler E, Román GC. Treatment of myelopathy in Sjögren syndrome with a combination of prednisone and cyclophosphamide. Arch Neurol 2001 May; 58: 815-9
15. de Seze J, Devos D, Castelnovo G, et al. The prevalence of Sjögren syndrome in patients with primary progressive multiple sclerosis. Neurology 2001 Oct; 57 (2): 1359-63
16. Alexander E. Central nervous system disease in Sjögren's syndrome: new insights into immunopathogenesis. Rheum Dis Clin North Am 1992 Aug; 18 (3): 637-72
17. Alexander G, Provost TT, Stevens MB, et al. Sjögren syndrome: central nervous system manifestations. Neurology 1981 Nov; 31: 1391-6
18. Niemelä RK, Hakala M. Primary Sjögren's syndrome with severe central nervous system disease. Semin Arthritis Rheum 1999 Aug; 29 (1): 4-13
19. Alexander EL, Ranzenbach MR, Kumar AJ, et al. Anti-Ro(SS-A) autoantibodies in central nervous system disease associated with Sjögren's syndrome (CNS-SS): clinical, neuroimaging, and angiographic correlates. Neurology 1994 May; 44: 899-908
20. Ranzenbach MR, Plitt JR, Kumar AJ, et al. CNS disease in Sjögren's syndrome (CNS-SS): role of anti-Ro (SS-A) antibodies [abstract]. FASEB J 1991; 5: A1386
21. Ranzenbach MR, Kumar A, Rosenbaum AE, et al. Anti-Ro (SS-A) autoantibodies (A-RoAb) in the immunopathogenesis of serious focal CNS disease in Sjögren's syndrome (CNS-SS). Arthritis Rheum 1992; 35 Suppl.: S114
22. Rood MJ, Verschuuren JJ, van Duinen SG, et al. CNS involvement in primary Sjögren's syndrome: a case with a clue for the pathogenesis. J Neurol 2000; 247: 63-4
23. Bakchine S, Duyckaerts C, Hassine L, et al. Lésions neurologiques centrals et péripheriques au cours d'un syndrome de Gougerot- Sjögren's primitif: étude clinicopathologique d'un cas. Rev Neurol (Paris) 1991; 147: 368-75
24. Jonsson R, Haga HJ, Gordon T. Sjögren's syndrome. In: Koopman WJ, editor. Arthritis and allied conditions. Philadelphia (PA): Lippincott Williams & Wilkins, 2001: 1736-59
25. Tzioufas AG, Boumba DS, Skopouli FN, et al. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 1996; 39: 767-72
26. Skopouli FN, Dafni U, Ioannidis JP. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum 2000 Apr; 29 (5): 296-304
27. Sutcliffe N, Inanc M, Speight P, et al. Predictors of lymphoma development in primary Sjögren's syndrome. Semin Arthritis Rheum 1998 Oct; 28 (2); 80-7
28. Ménage P, de Toffol B, Degenne D, et al. Syndrome de Gougerot-Sjögren's primitif. Rev Neurol (Paris) 1993; 149: 554-6
29. Hawley J, Hendricks W. Treatment of Sjögren's syndrome myelopathy with azathioprine and steroids [letter]. Arch Neurol 2002 May; 59: 875
30. Wright R, O'Duffy J, Rodriguez M. Improvement of myelopathy in Sjögren's syndrome with chlorambucil and prednisone therapy. Neurology 1999 Jan; 52 (2): 386-8
31. Hermisson M, Klein R, Schmidt F, et al. Myelopathy in primary Sjögren's syndrome: diagnostic and therapeutic aspects. Acta Neurol Scand 2002; 105: 450-3
32. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. N Engl J Med 1984 Dec; 311 (24): 1528-33
33. Tew KD, Colvin OM, Chabner BA. Alkylating agents. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy. Philadelphia (PA): Lippincott Williams & Wilkins, 2001: 373-414
34. Price EJ, Rigby SP, Clancy U, et al. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome. J Rheumatol 1998; 25 (5): 896-9
35. Drosos AA, Skopouli FN, Galanopoulou VK, et al. Cyclosporine A therapy in patients with primary Sjögren's syndrome: results at one year. Scand J Rheumatol Suppl 1986; 61: 246-9
36. van der Reijden WA, Vissink A, Veerman EC, et al. Treatment of oral dryness related complaints (xerostomia) in Sjögren's syndrome. Ann Rheum Dis 1999; 58: 465-73
37. Skopouli FN, Jagiello P, Tsifetaki N, et al. Methotrexate in primary Sjögren's syndrome. Clin Exp Rheumatol 1996; 14: 555-8
38. Schuna AA. Rheumatoid arthritis. In: Dipiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: a pathophysiologic approach. New York (NY): McGraw-Hill, 2002: 1623-58
39. McEvoy GK, editor. American Hospital formulary service drug information. Bethesda (MD): American Society of Health-System Pharmacists, 2002
40. Konttinen YT, Kinnunen E, von Bonsdorff M, et al. Acute transverse myelopathy successfully treated with plasmapheresis and prednisone in a patient with primary Sjögren's syndrome. Arthritis Rheum 1987 Mar; 30 (3): 339-44
41. Canhão H, Fonseca JE, Rosa A. Intravenous gammaglobulin in the treatment of central nervous system vasculitis associated with Sjögren's syndrome. J Rheumatol 2000; 27 (4): 1102-3
42. Mariette X. Current and potential treatments for primary Sjögren's syndrome. Joint Bone Spine 2002; 69: 363-6
43. Steinfeld SD, Demols P, Salmon I, et al. Infliximab in patients with primary Sjögren's syndrome: a pilot study. Arthritis Rheum 2001 Oct; 44 (10): 2371-5
44. Caroyer JM, Manto MU, Steinfeld SD. Severe sensory neuronopathy responsive to infliximab in primary Sjögren's syndrome. Neurology 2002 Oct; 59 (1): 1113-4